Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is now the most common chronic liver condition in the United States. Current data suggest it affects approximately 30 percent of the general population and as many as 50 to 90 percent of individuals with obesity or metabolic syndrome. MASLD is defined by the accumulation of excess fat in the liver—typically greater than 5 percent of liver weight—in the absence of significant alcohol consumption. In its early stages, MASLD often causes little to no overt inflammation or liver cell injury; however, fat accumulation alone can impair liver function and disrupt metabolic signaling. If left unaddressed, MASLD can progress to a more severe condition known as metabolic dysfunction–associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH). MASH is characterized by liver fat accumulation accompanied by inflammation, hepatocellular injury, fibrosis, and, in advanced cases, cirrhosis or liver failure.
MASLD is increasingly recognized as a systemic metabolic disease rather than a condition isolated to the liver. Numerous studies have shown that MASLD is associated with significantly increased all-cause mortality, largely driven by higher rates of cardiovascular disease, type 2 diabetes, chronic kidney disease, cirrhosis, and both liver-related and non–liver-related cancers, including gastrointestinal malignancies. In some populations, MASLD has been associated with up to a 70 percent increase in mortality risk, underscoring its growing public health significance.
One of the challenges in addressing MASLD is that it is often a silent disease. Many individuals have no symptoms at all, while others may experience nonspecific complaints such as fatigue, weakness, unintentional weight changes, or a dull, aching discomfort in the right upper abdomen. Although liver biopsy remains the gold standard for diagnosis, its routine use is controversial due to its invasive nature. In clinical practice, MASLD is often suspected based on laboratory findings such as elevated alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), triglycerides, fasting insulin, or markers of insulin resistance. When laboratory findings are suggestive, imaging studies such as abdominal ultrasound may be used to confirm hepatic steatosis, often revealing a liver that appears brighter or more echogenic compared to normal tissue.
The development of MASLD is strongly linked to metabolic dysfunction. Major contributors include diets high in processed foods and fructose, obesity, insulin resistance, type 2 diabetes, dyslipidemia, and sedentary lifestyle patterns. A central metabolic mechanism driving MASLD is de novo lipogenesis, a process by which excess carbohydrates—particularly fructose—are converted into triglycerides within the liver. This explains the frequent coexistence of fatty liver, elevated triglycerides, and insulin resistance. Dysregulation of this pathway is closely associated with metabolic syndrome and plays a key role in disease progression.
At present, there are no FDA-approved medications specifically indicated for the treatment of MASLD. As a result, management focuses on lifestyle modification and targeted nutritional and metabolic support. Reducing fructose intake is a cornerstone of treatment, particularly from sources such as high-fructose corn syrup found in many processed foods and sweetened beverages. Fructose promotes fat accumulation in the liver, impairs fat breakdown, worsens insulin resistance, and increases oxidative stress. Supporting liver fat export is also critical, as the liver relies on choline—primarily in the form of phosphatidylcholine—to package and remove triglycerides. Choline supplementation may be helpful, and in select cases, phosphatidylcholine injections may be used to further support hepatic fat metabolism. Additional evidence-supported interventions include vitamin E for reducing oxidative stress and inflammation, berberine for improving insulin sensitivity, and curcumin for its anti-inflammatory effects. Other supportive nutrients may include N-acetylcysteine (NAC), omega-3 fatty acids, milk thistle, L-carnitine, S-adenosylmethionine (SAMe), and epigallocatechin gallate (EGCG), depending on individual needs.
MASLD is largely a preventable and, in many cases, reversible condition when addressed early through targeted lifestyle, nutritional, and metabolic interventions. Identifying risk factors before progression to advanced liver disease is critical. If you are concerned about fatty liver disease, metabolic health, or are interested in learning more about phosphatidylcholine injections and personalized treatment options, you are encouraged to contact our office to schedule a consultation.
True healing begins at the root. If you’re ready for a personalized, root-cause approach to your health, we invite you to contact our office to schedule a consultation.
